Back to search results

MET097 for Overweight or Obesity

This study is looking at a new injectable medicine called MET097 for adults who are overweight or have obesity. You might be able to join if you are 18 or older and have a Body Mass Index (BMI) of 30 or higher, or a BMI between 27 and 30 with at least one weight-related health problem like high blood pressure or sleep apnea. People with diabetes are not eligible. The study will compare MET097 to a placebo (an inactive substance) given once a week as a shot under the skin. Researchers want to see how much MET097 helps with weight loss and if it's safe. The main goal is to measure the change in body weight after 64 weeks. The study is planning to enroll about 3578 people, but the current recruitment status is unclear.

Study design
This study is testing MET097 against a placebo in a large group of people (3578 planned participants). It is an interventional study, meaning participants will receive either the study drug or a placebo.
What's involved
You would receive a once-weekly injection of either MET097 or a placebo. The study will last for 84 weeks, with the main assessment at 64 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at Week 64, and secondary outcomes are measured at Week 84, indicating follow-up throughout this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07311850

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatment
Pfizer
~3,578 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:MET097Placebo

At a glance

Recruiting sites
0 of 171 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change from baseline in body weight
Measured over Baseline (Day 0) to Week 64

Conditions

Obesity and Overweight

Explore related trials

ObesityOverweight

Where it's being run

171 sites across 32 states
Poland32
United Kingdom23
Germany18
Bulgaria14
Romania11
Czechia9
Slovakia9
Spain7

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to \<30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

Exclusion

Have any form of diabetes
Have a self-reported body weight change \> 5 kg (11 pounds) within 3 months prior to Screening
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease

What this trial measures

  • Percent change from baseline in body weightBaseline (Day 0) to Week 64